Revvity, Inc. (RVTY) Balance Sheet

The reduction in total assets and liabilities indicates a deliberate portfolio simplification, with the divestiture of the Applied business reducing the asset base. Debt reduction from $4.0B to $3.3B over the same period suggests a strategic focus on strengthening the balance sheet, though the pace of deleveraging has slowed in recent quarters. This trajectory implies a more focused, less capital-intensive entity, but the stability in asset levels over the last two quarters suggests the transformation is largely complete.

The D/E ratio of 0.46 is moderate and below peers like Waters (0.58) and Bruker (0.81), suggesting a conservative capital structure. The absolute debt level of $3.3B appears manageable relative to cash flow, and the company's ability to reduce debt by $700M over two years indicates strong cash generation. However, the recent stabilization in debt levels suggests the company may be prioritizing capital returns over further deleveraging, which could increase refinancing risk if rates rise.

The high goodwill balance, largely from the BioLegend acquisition, indicates that a significant portion of the company's value is tied to acquired intangibles rather than physical assets. This suggests a business model that is less capital-intensive, consistent with the declining capex intensity observed in cash flow. However, the concentration in goodwill raises impairment risk if growth expectations are not met, particularly in the Life Sciences segment.

The increase in retained earnings indicates cumulative profitability, but the decline in total equity from $7.9B to $7.2B over the same period suggests that capital returns (buybacks and dividends) are outpacing retained earnings growth. This is consistent with the aggressive buyback program noted in cash flow analysis, which may enhance EPS but could also signal limited organic investment opportunities. The equity base remains substantial, providing a cushion against potential write-downs.

The sharp decline in the current ratio from 3.60 to 1.80 suggests that the company has normalized its working capital after the divestiture, possibly by reducing excess cash or paying down liabilities. Cash of $1.0B provides a reasonable buffer against short-term obligations, but the trend warrants monitoring as the ratio approaches the peer average of around 1.7. The liquidity position appears adequate for operational needs, though less robust than in prior periods.